Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumab

Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximabПодробнее

Overview of a Phase II clinical trial of isatuximabПодробнее

Robert Rifkin, MD, explains the key features of biosimilarsПодробнее

An update on GMMG HD7: Isa-RVd vs RVd & lenalidomide-isatuximab vs lenalidomide maintenance in NDMMПодробнее

Dr. Rifkin on Split Dosing of Daratumumab in MyelomaПодробнее

Isatuximab: a ‘next-generation monoclonal antibody’Подробнее

Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promisingПодробнее

Choosing between isatuximab & daratumumab in multiple myelomaПодробнее

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory MyelomaПодробнее

Isatuximab and pomalidomide for the treatment of MMПодробнее

The safety and efficacy of isatuximab for R/R myeloma: insights from ICARIA-MM, IKEMA & CANDORПодробнее

Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple MyelomaПодробнее

Highlighting Therapeutic Options in Later Lines for Multiple MyelomaПодробнее

Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterizationПодробнее

MM-6 Trial: In-class transition to Ixazomib in Newly Diagnosed Myeloma | Robert Rifkin, MD | #ASH24Подробнее

IKEMA: isatuximab + Kd improves response and PFS in R/R myelomaПодробнее

Isatuximab phase 3 study in patients with relapsed and refractory multiple myelomaПодробнее

Dr Robert Rifkin Outlines Recent Treatment Advances in Multiple MyelomaПодробнее

MOA and Safety Profile of Isatuximab from the ICARIA StudyПодробнее